Day Two At BIO CEO: Deal Value Up, Deal Volume Down
This article was originally published in The Pink Sheet Daily
Executive Summary
The Let’s Make a Deal panel looked forward to more big product-focused Genzyme/Alnylam type deals in 2014 in a deal landscape changed by a robust pubic market and by caution on the part of big pharma; BIO chair Rachel King on 2014 priorities; Stallergenes prepares to launch Oralair
You may also be interested in...
Riding High On Investor Enthusiasm, BIO CEO 2014 Opens In New York
Sanofi’s Chris Viehbacher says mutual respect, cultural understanding and close communication are keys to relationships with partners Alnylam and Regeneron; BIO survey confirms investor optimism for 2014; and RNAi panelists reflect on recent IPO glories.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.